ArticleHeliyon2024
Successful therapy of a critically ill non-small cell lung cancer patient with compound mutations in
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 4 citations in OpenAlex.
- Furmonertinib in uncommon EGFR-mutated non-small cell lung cancer with central nervous system metastases: A retrospective cohort study.International journal of cancer · 2025Article
- Efficacy and safety of furmonertinib in patients with EGFR‑mutant advanced lung adenocarcinoma after failure of multiple lines of therapy: A single‑center retrospective study.Oncology letters · 2025Article
- Treatment of advanced lung adenocarcinoma with EGFR L833V/H835L compound mutations using furmonertinib: two case reports and literature review.Frontiers in medicine · 2025Article
- Favorable response to third-generation TKI furmonertinib in a patient with early-stage non-small cell lung cancer harboring rare compound EGFR mutations: Exon 18 G719C and Exon 20 S768I - A Case Report.Frontiers in oncology · 2025Article
- [Advances in Diagnosis and Targeted Therapy of G719X/L861Q/S768I Mutant Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Somatic mutations in epidermal growth factor receptor ( Case presentation: In this study, the G719X/S768I compound mutations were detected in a critically ill NSCLC patient. This patient received furmonertinib for 14 months and successfully responded to the treatment. The present case report highlights the ideal clinical response, with ongoing follow-up. Conclusion: We report the successful treatment of a critically ill NSCLC patient carrying rare compound
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.